Oncoprotein immunoreactivity in human endocrine tumours

M. Roncalli, D. R. Springall, I. M. Varndell, V. V. Gaitonde, Q. Hamid, N. B N Ibrahim, L. Grimelius, E. Wilander, J. M. Polak, G. Coggi

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Abnormally expressed oncogenes are implicated in neoplastic transformation. We have investigated a series of endocrine tumours using immunocytochemistry as a first screening tool to detect oncogene expression. Paraffin sections of 44 pulmonary small cell carcinomas, 15 pulmonary atypical carcinoids, 12 bronchial carcinoids, 28 medullary thyroid carcinomas, 27 phaeochromocytomas, and 17 insulinomas were immunostained with antibodies to c-erbB-2, c-myc, L-myc, and N-myc. Diffuse immunoreactivity was detectable for c-erbB-2 in 8 out of 44 (18 per cent) pulmonary small cel carcinomas, 3 out of 15 (20 per cent) pulmonary atypical carcinoids, and 6 out of 27 (22 per cent) phaeochromocytomas; for c-myc in 18 out of 44 (41 per cent) pulmonary small cell carcinomas and 5 out of 15 (33 per cent) pulmonary atypical carcinoids; for N-myc in 6 out of 28 (21 per cent) medullary thyroid carcinomas; and for L-myc in 4 out of 27 (15 per cent) phaeochromocytomas. There was considerable intratumoral and intertumoral heterogeneity and, in each tumour group, no relationship was found between tumour pattern, mitotic index, and oncoprotein immunoreactivity. These results suggest that oncogene products are present in a proportion of endocrine tumours, and that specific oncoproteins seem to be related to tumour type but not to other histopathological findings. Thus, oncoprotein detection may be a useful tool for identifying subsets of endocrine tumours that are not otherwise recognizable morphologically.

Original languageEnglish
Pages (from-to)117-127
Number of pages11
JournalJournal of Pathology
Volume163
Issue number2
Publication statusPublished - 1991

Fingerprint

Oncogene Proteins
Carcinoid Tumor
Lung
Pheochromocytoma
Neoplasms
Small Cell Carcinoma
Oncogenes
Insulinoma
Mitotic Index
Paraffin
Immunohistochemistry
Carcinoma
Antibodies

Keywords

  • c-erbB-2
  • c-myc
  • Endocrine tumours
  • Immunocytochemistry
  • L-myc
  • N-myc
  • Oncogenes
  • Oncoproteins

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Roncalli, M., Springall, D. R., Varndell, I. M., Gaitonde, V. V., Hamid, Q., Ibrahim, N. B. N., ... Coggi, G. (1991). Oncoprotein immunoreactivity in human endocrine tumours. Journal of Pathology, 163(2), 117-127.

Oncoprotein immunoreactivity in human endocrine tumours. / Roncalli, M.; Springall, D. R.; Varndell, I. M.; Gaitonde, V. V.; Hamid, Q.; Ibrahim, N. B N; Grimelius, L.; Wilander, E.; Polak, J. M.; Coggi, G.

In: Journal of Pathology, Vol. 163, No. 2, 1991, p. 117-127.

Research output: Contribution to journalArticle

Roncalli, M, Springall, DR, Varndell, IM, Gaitonde, VV, Hamid, Q, Ibrahim, NBN, Grimelius, L, Wilander, E, Polak, JM & Coggi, G 1991, 'Oncoprotein immunoreactivity in human endocrine tumours', Journal of Pathology, vol. 163, no. 2, pp. 117-127.
Roncalli M, Springall DR, Varndell IM, Gaitonde VV, Hamid Q, Ibrahim NBN et al. Oncoprotein immunoreactivity in human endocrine tumours. Journal of Pathology. 1991;163(2):117-127.
Roncalli, M. ; Springall, D. R. ; Varndell, I. M. ; Gaitonde, V. V. ; Hamid, Q. ; Ibrahim, N. B N ; Grimelius, L. ; Wilander, E. ; Polak, J. M. ; Coggi, G. / Oncoprotein immunoreactivity in human endocrine tumours. In: Journal of Pathology. 1991 ; Vol. 163, No. 2. pp. 117-127.
@article{f66b496d4856436badcc4e30b6647b97,
title = "Oncoprotein immunoreactivity in human endocrine tumours",
abstract = "Abnormally expressed oncogenes are implicated in neoplastic transformation. We have investigated a series of endocrine tumours using immunocytochemistry as a first screening tool to detect oncogene expression. Paraffin sections of 44 pulmonary small cell carcinomas, 15 pulmonary atypical carcinoids, 12 bronchial carcinoids, 28 medullary thyroid carcinomas, 27 phaeochromocytomas, and 17 insulinomas were immunostained with antibodies to c-erbB-2, c-myc, L-myc, and N-myc. Diffuse immunoreactivity was detectable for c-erbB-2 in 8 out of 44 (18 per cent) pulmonary small cel carcinomas, 3 out of 15 (20 per cent) pulmonary atypical carcinoids, and 6 out of 27 (22 per cent) phaeochromocytomas; for c-myc in 18 out of 44 (41 per cent) pulmonary small cell carcinomas and 5 out of 15 (33 per cent) pulmonary atypical carcinoids; for N-myc in 6 out of 28 (21 per cent) medullary thyroid carcinomas; and for L-myc in 4 out of 27 (15 per cent) phaeochromocytomas. There was considerable intratumoral and intertumoral heterogeneity and, in each tumour group, no relationship was found between tumour pattern, mitotic index, and oncoprotein immunoreactivity. These results suggest that oncogene products are present in a proportion of endocrine tumours, and that specific oncoproteins seem to be related to tumour type but not to other histopathological findings. Thus, oncoprotein detection may be a useful tool for identifying subsets of endocrine tumours that are not otherwise recognizable morphologically.",
keywords = "c-erbB-2, c-myc, Endocrine tumours, Immunocytochemistry, L-myc, N-myc, Oncogenes, Oncoproteins",
author = "M. Roncalli and Springall, {D. R.} and Varndell, {I. M.} and Gaitonde, {V. V.} and Q. Hamid and Ibrahim, {N. B N} and L. Grimelius and E. Wilander and Polak, {J. M.} and G. Coggi",
year = "1991",
language = "English",
volume = "163",
pages = "117--127",
journal = "Journal of Pathology",
issn = "0022-3417",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

TY - JOUR

T1 - Oncoprotein immunoreactivity in human endocrine tumours

AU - Roncalli, M.

AU - Springall, D. R.

AU - Varndell, I. M.

AU - Gaitonde, V. V.

AU - Hamid, Q.

AU - Ibrahim, N. B N

AU - Grimelius, L.

AU - Wilander, E.

AU - Polak, J. M.

AU - Coggi, G.

PY - 1991

Y1 - 1991

N2 - Abnormally expressed oncogenes are implicated in neoplastic transformation. We have investigated a series of endocrine tumours using immunocytochemistry as a first screening tool to detect oncogene expression. Paraffin sections of 44 pulmonary small cell carcinomas, 15 pulmonary atypical carcinoids, 12 bronchial carcinoids, 28 medullary thyroid carcinomas, 27 phaeochromocytomas, and 17 insulinomas were immunostained with antibodies to c-erbB-2, c-myc, L-myc, and N-myc. Diffuse immunoreactivity was detectable for c-erbB-2 in 8 out of 44 (18 per cent) pulmonary small cel carcinomas, 3 out of 15 (20 per cent) pulmonary atypical carcinoids, and 6 out of 27 (22 per cent) phaeochromocytomas; for c-myc in 18 out of 44 (41 per cent) pulmonary small cell carcinomas and 5 out of 15 (33 per cent) pulmonary atypical carcinoids; for N-myc in 6 out of 28 (21 per cent) medullary thyroid carcinomas; and for L-myc in 4 out of 27 (15 per cent) phaeochromocytomas. There was considerable intratumoral and intertumoral heterogeneity and, in each tumour group, no relationship was found between tumour pattern, mitotic index, and oncoprotein immunoreactivity. These results suggest that oncogene products are present in a proportion of endocrine tumours, and that specific oncoproteins seem to be related to tumour type but not to other histopathological findings. Thus, oncoprotein detection may be a useful tool for identifying subsets of endocrine tumours that are not otherwise recognizable morphologically.

AB - Abnormally expressed oncogenes are implicated in neoplastic transformation. We have investigated a series of endocrine tumours using immunocytochemistry as a first screening tool to detect oncogene expression. Paraffin sections of 44 pulmonary small cell carcinomas, 15 pulmonary atypical carcinoids, 12 bronchial carcinoids, 28 medullary thyroid carcinomas, 27 phaeochromocytomas, and 17 insulinomas were immunostained with antibodies to c-erbB-2, c-myc, L-myc, and N-myc. Diffuse immunoreactivity was detectable for c-erbB-2 in 8 out of 44 (18 per cent) pulmonary small cel carcinomas, 3 out of 15 (20 per cent) pulmonary atypical carcinoids, and 6 out of 27 (22 per cent) phaeochromocytomas; for c-myc in 18 out of 44 (41 per cent) pulmonary small cell carcinomas and 5 out of 15 (33 per cent) pulmonary atypical carcinoids; for N-myc in 6 out of 28 (21 per cent) medullary thyroid carcinomas; and for L-myc in 4 out of 27 (15 per cent) phaeochromocytomas. There was considerable intratumoral and intertumoral heterogeneity and, in each tumour group, no relationship was found between tumour pattern, mitotic index, and oncoprotein immunoreactivity. These results suggest that oncogene products are present in a proportion of endocrine tumours, and that specific oncoproteins seem to be related to tumour type but not to other histopathological findings. Thus, oncoprotein detection may be a useful tool for identifying subsets of endocrine tumours that are not otherwise recognizable morphologically.

KW - c-erbB-2

KW - c-myc

KW - Endocrine tumours

KW - Immunocytochemistry

KW - L-myc

KW - N-myc

KW - Oncogenes

KW - Oncoproteins

UR - http://www.scopus.com/inward/record.url?scp=0025971902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025971902&partnerID=8YFLogxK

M3 - Article

C2 - 1673155

AN - SCOPUS:0025971902

VL - 163

SP - 117

EP - 127

JO - Journal of Pathology

JF - Journal of Pathology

SN - 0022-3417

IS - 2

ER -